Intralesional Tetracycline Injection in the Treatment of Chalazia (TET)
|ClinicalTrials.gov Identifier: NCT01763437|
Recruitment Status : Withdrawn (Investigator left the institution)
First Posted : January 8, 2013
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Chalazia Chalazion||Drug: Tetracycline||Early Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Intralesional Tetracycline Injection in the Treatment of Chalazia|
|Study Start Date :||March 2014|
|Estimated Primary Completion Date :||March 2015|
|Estimated Study Completion Date :||March 2015|
No Intervention: Observation
30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
- Lesion size [ Time Frame: 4 weeks ]The size of the lesion will be measured as well as photographed. Photographs will be reviewed by a masked chalazion photograph reviewer.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763437
|United States, Ohio|
|Cleveland Clinic Cole Eye Institute|
|Cleveland, Ohio, United States, 44145|
|Principal Investigator:||Julian D Perry, M.D.||Cleveland Clinic Cole Eye Institute|